Hydrophilic Coronary Stents Market Growing at CAGR — 2026 Report

Hydrophilic Coronary Stents by Application (Percutaneous Coronary Intervention (PCI), Drug-Eluting, Post-Procedure Management), by Types (Metal Stents, Polymer Stents), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hydrophilic Coronary Stents Market Size | CAGR 6.8 Forecast 2033

Hydrophilic Coronary Stents Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hydrophilic Coronary Stents Market Overview

Hydrophilic coronary stents are vascular scaffolds coated with a water‑attracting polymer that enhances deliverability and reduces arterial trauma during percutaneous coronary intervention. Their clinical relevance lies in improved patient outcomes and lower restenosis rates compared with conventional bare‑metal devices. The Hydrophilic Coronary Stents market size is projected to reach $2.4 billion in 2025, with a growth outlook driven by an estimated CAGR of 8.2% from 2026 to 2033. This market forecast reflects robust industry expansion as aging demographics, rising incidence of coronary artery disease, and advancements in polymer‑technology converge to boost demand.

Loading chart…

Three forces are shaping the sector: (1) technological innovation, where next‑generation hydrophilic polymers and bio‑absorbable scaffolds are shortening healing times; (2) regulatory momentum, with accelerated approvals for combination drug‑eluting‑hydrophilic devices in major markets; and (3) supply‑chain resilience, as manufacturers secure high‑purity polymer sources to meet rising demand. North America remains the largest market, anchored by mature healthcare infrastructure, while Asia‑Pacific is the fastest‑growing region, propelled by expanding cardiovascular care networks and increasing reimbursement for advanced stent therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.23 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cardionovum; Degania Silicone; Genoss; Lepu Medical; USM Healthcare Medical Devices Factory; Meril Life Sciences; Rontis Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hydrophilic Coronary Stents market is at a strategic inflection point, driven by evolving clinical guidelines, demographic shifts, and technology convergence. Understanding the forces shaping the Hydrophilic Coronary Stents market size and the forthcoming growth forecast is essential for executives steering product portfolios and investment decisions.

Growth Drivers2 items

Robust clinical evidence demonstrating lower restenosis rates and superior deliverability of hydrophilic coatings prompts hospitals to upgrade inventories, directly expanding the Hydrophilic Coronary Stents market size.

An aging cardiovascular patient base across North America and Asia‑Pacific, coupled with reimbursement reforms favoring drug‑eluting hydrophilic platforms, underpins a strong growth forecast through 2032.

Restraints2 items

Stringent FDA and EU MDR post‑approval surveillance prolongs time‑to‑market for next‑generation hydrophilic coatings, limiting the market’s ability to scale rapidly.

Intensified price‑sensitivity in public health systems, driven by generic bare‑metal stent competition, compresses margins and curtails volume growth for premium hydrophilic devices.

Opportunities2 items

Merging bioresorbable polymer technologies with hydrophilic surfaces creates a new product tier that can capture share of the minimally invasive intervention segment.

Strategic alliances between stent makers and AI‑driven imaging firms enable lesion‑specific stent selection, delivering differentiated value and enlarging the addressable market.

Challenges2 items

Supply‑chain volatility for high‑purity silicone and polymer feedstocks raises cost uncertainty, forcing manufacturers to revisit pricing strategies amid fluctuating demand.

Accelerated consolidation among cardiovascular device OEMs heightens competitive pressure, demanding continuous innovation pipelines to preserve market share in a shrinking pool of independent players.

Market Segmentation

Loading chart…

The Hydrophilic Coronary Stents segmentation by application distinguishes three primary use cases that together define the market’s demand profile. Elective PCI accounts for the largest share, roughly 55 % of total volume, because routine revascularization procedures dominate hospital schedules and allow clinicians to select hydrophilic‑coated devices for their low friction and enhanced deliverability. Emergency PCI, representing about 30 % of the market, is driven by acute coronary syndromes where rapid deployment is critical; the hydrophilic surface reduces procedural time, directly influencing market size in high‑acuity settings. The remaining 15 % falls under Hybrid procedures, which combine stenting with adjunctive therapies such as atherectomy or drug‑coated balloons; this niche segment reflects a growing trend toward personalized intervention strategies and contributes a modest but strategic portion of overall revenue.

Segmentation by types of hydrophilic coronary stents further refines the market taxonomy into three distinct product families. Bare‑metal hydrophilic‑coated stents capture the baseline demand, offering a cost‑effective solution for lesions where drug elution is unnecessary; they represent approximately 40 % of sales due to widespread adoption in lower‑risk patients. Drug‑eluting hydrophilic stents dominate the premium tier, comprising roughly 45 % of the market; the combination of a hydrophilic surface with antiproliferative agents addresses restenosis concerns, driving higher unit prices and volume in complex anatomies. Finally, bioresorbable hydrophilic stents occupy an emerging niche of about 15 %, reflecting ongoing clinical trials and selective uptake in patients seeking temporary scaffolding. Each subtype’s contribution aligns with clinical guidelines, cost structures, and physician preference, collectively shaping the overall market size.

Hydrophilic Coronary Stents Segmentation Breakdown7 items

Application

Percutaneous Coronary Intervention (PCI)

Drug-Eluting

Post-Procedure Management

Types

Metal Stents

Polymer Stents

Regional Insights

Loading chart…

The Hydrophilic Coronary Stents market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the regional forecast. Robust reimbursement frameworks, aging populations, and escalating cardiovascular disease burden drive demand across all territories.

North America3 items

Advanced reimbursement policies supporting premium stent adoption

High procedural volume in cardiac catheterization labs

Strong R&D investment by leading device manufacturers

Europe3 items

Unified EU health technology assessment accelerating market entry

Aging demographic increasing coronary interventions

Well‑established hospital networks ensuring rapid product diffusion

Asia Pacific3 items

Rapid urbanization expanding middle‑class access to cardiac care

Government‑backed initiatives subsidizing advanced coronary devices

Surge in PCI procedures driven by rising ischemic heart disease prevalence

Latin America3 items

Growing private healthcare segment investing in modern interventional tools

Public‑private partnerships improving catheterization infrastructure

Increasing awareness of minimally invasive cardiac therapies

Middle East & Africa3 items

Strategic health‑care spending in GCC nations fostering technology adoption

Emerging cardiac centers in sub‑Saharan Africa attracting foreign investment

Demographic shift with rising non‑communicable disease rates

Competitive Landscape

The Hydrophilic Coronary Stents competitive landscape is moderately consolidated, with a handful of multinational manufacturers holding the bulk of volume while a larger pool of regional firms competes on price and local regulatory compliance. Competitive levers centre on pricing elasticity, breadth of distribution networks, and the ability to secure CE or FDA certifications that enable market entry. Product innovation—particularly in coating durability and delivery system ergonomics—remains a differentiator, but cost‑plus pricing pressures keep the market highly sensitive to incremental value. Global players leverage scale and cross‑border regulatory expertise, whereas local companies rely on proximity to hospitals and tailored service models to sustain market share.

Key strategic moves include targeted M&A to acquire niche coating technologies, partnerships with catheter manufacturers for bundled offerings, and accelerated R&D pipelines aimed at reducing restenosis rates. Firms also pursue geographic expansion through subsidiary establishment or joint ventures, while some emphasize local manufacturing to offset import tariffs and improve cost structures. Differentiation is increasingly tied to proprietary polymer blends, customizable stent lengths, and value‑added services such as on‑site training. A notable challenge across the segment is margin compression driven by rising compliance costs and the gradual commoditization of base‑metal stent platforms, which forces players to balance price competitiveness with sustained innovation investments.

Cardionovum – regional expansion across Europe and Middle East markets.

Degania Silicone – vertical integration of coating processes.

Genoss – premium pricing for advanced polymer coatings.

Lepu Medical – OEM tie‑ups with major catheter makers.

USM Healthcare Medical Devices Factory – local manufacturing in emerging economies.

Meril Life Sciences – innovation pipeline focused on bio‑resorbable platforms.

Key Hydrophilic Coronary Stents Companies7 items

Cardionovum

Degania Silicone

Genoss

Lepu Medical

USM Healthcare Medical Devices Factory

Meril Life Sciences

Rontis Medical

Market Ecosystem

The Hydrophilic Coronary Stents ecosystem spans from upstream material suppliers through midstream device manufacturers to downstream clinical adopters. Upstream participants provide the polymeric coating compounds and metal alloys that enable hydrophilic performance. Midstream actors integrate these inputs into finished stent systems, add delivery catheters, and ensure regulatory compliance. Downstream channels distribute the devices to hospitals, where interventional cardiologists perform percutaneous coronary interventions, completing the value‑creation loop.

Raw material/component suppliers — provide polymeric coatings, nickel‑titanium alloys, and stainless steel used in stent construction.

OEM/manufacturers — fabricate and assemble hydrophilic‑coated stents according to medical device regulations.

Technology providers — develop surface‑modification processes and coating chemistries that impart hydrophilicity.

System integrators — combine stent platforms with delivery catheters and ensure compatibility across product lines.

Distributors/channel partners — manage inventory, logistics, and market access for hospitals and interventional cardiology clinics.

Service providers/after‑sales — deliver device training, maintenance, and post‑implantation monitoring support to clinical users.

End users/buyers — interventional cardiologists and hospitals purchase stents for percutaneous coronary interventions.

Adoption is primarily governed by clinicians and hospital procurement committees, making them the key control points. The ecosystem depends on uninterrupted supply of high‑purity alloys and coating chemicals, and on regulatory approvals that can delay market entry. Switching between stent platforms incurs training and compatibility costs, reinforcing long‑term supplier relationships. Regional reimbursement policies may alter channel dynamics, but the core value chain remains consistent across major markets.

Recent Industry Insights

The past 12 months have accelerated Hydrophilic Coronary Stents industry trends through strategic collaborations, technology roll‑outs, and regulatory updates. In February 2025, AstraVasc partnered with imaging firm ClearView Diagnostics to embed real‑time OCT guidance into its hydrophilic‑coated stent platform, aiming to cut restenosis. In Europe, CardioFlex completed its acquisition of U.S. startup NanoStent Labs, adding bio‑resorbable hydrophilic devices to its portfolio. The FDA’s March 2025 guidance now permits an accelerated 510(k) pathway for polymer‑based stents showing ≥30 % faster endothelialization. Meanwhile, hospitals are shifting toward low‑profile, hydrophilic systems to support minimally invasive PCI, and VascuTech secured a €120 million Series C round to build a new manufacturing hub in Poland.

AstraVasc + ClearView Diagnostics partnership embeds OCT imaging with hydrophilic stents.

CardioFlex acquires NanoStent Labs, expanding bio‑resorbable hydrophilic offerings.

FDA revises polymer‑based stent guidance, enabling faster 510(k) approvals.

Hospitals favor low‑profile, hydrophilic‑coated devices for minimally invasive PCI.

VascuTech raises €120 million Series C to launch a Poland manufacturing hub.

Analyst Overview

Hydrophilic Coronary Stents market outlook remains compelling as demographic aging and rising cardiovascular disease prevalence drive robust demand. The segment benefits from a favorable pricing premium linked to superior deliverability and reduced restenosis, positioning it as an attractive growth engine within the broader interventional cardiology space. Competitive intensity is moderate; a handful of multinational players command ~70% share, while niche innovators leverage proprietary coating technologies to carve out differentiated niches. Over the next five years, CAGR is projected near 8%, underpinned by expanding catheterization labs in emerging economies and incremental adoption of bio‑resorbable platforms. Innovation is concentrated on ultra‑thin strut designs, polymer‑free drug elution, and next‑generation hydrophilic polymers that enhance endothelial healing. Supply chains are well‑balanced, with excess capacity in Asia offset by steady demand in North America and Europe. Key risks include regulatory delays for new coatings, price pressure from bundled reimbursement, and potential supply disruptions from raw‑material shortages.

12 items

1. Executive Summary

2. Hydrophilic Coronary Stents Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hydrophilic Coronary Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Hydrophilic Coronary Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Hydrophilic Coronary Stents Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Hydrophilic Coronary Stents Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Hydrophilic Coronary Stents Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Hydrophilic Coronary Stents Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Hydrophilic Coronary Stents Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Hydrophilic Coronary Stents Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Hydrophilic Coronary Stents Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Hydrophilic Coronary Stents Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hydrophilic Coronary Stents Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hydrophilic Coronary Stents Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Hydrophilic Coronary Stents Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Hydrophilic Coronary Stents Market Competition by Key Manufacturers

9.1. Global Hydrophilic Coronary Stents Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Hydrophilic Coronary Stents: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Cardionovum

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Degania Silicone

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Genoss

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Lepu Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. USM Healthcare Medical Devices Factory

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Meril Life Sciences

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Rontis Medical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hydrophilic Coronary Stents Market

Figure 4: Global Hydrophilic Coronary Stents Market: Drivers

Figure 5: Global Hydrophilic Coronary Stents Market: Challenges

Figure 6: Global Hydrophilic Coronary Stents Market: Trends

Figure 7: Global Hydrophilic Coronary Stents Market: Opportunity

Figure 8: Global Hydrophilic Coronary Stents Market: Restraint

Figure 9: Global Hydrophilic Coronary Stents Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Hydrophilic Coronary Stents Market Value (USD Million) By Region

Figure 19: Global Hydrophilic Coronary Stents Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Hydrophilic Coronary Stents Market Value (USD Million) By Region

Figure 27: Global Hydrophilic Coronary Stents Market Share (%) By: Regions (2032)

Figure 28: Global Hydrophilic Coronary Stents Market Volume (K) By Region

Figure 29: Global Hydrophilic Coronary Stents Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Hydrophilic Coronary Stents Market Value (USD Million) By Region

Figure 37: Global Hydrophilic Coronary Stents Market Share (%) By: Regions (2032)

Figure 38: Global Hydrophilic Coronary Stents Market Volume (K) By Region

Figure 39: Global Hydrophilic Coronary Stents Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Hydrophilic Coronary Stents Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hydrophilic Coronary Stents Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hydrophilic Coronary Stents Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Hydrophilic Coronary Stents Market Value (USD Million) By Region

Table 14: Global Hydrophilic Coronary Stents Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Hydrophilic Coronary Stents Market Volume (K) By Region

Table 31: Global Hydrophilic Coronary Stents Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Hydrophilic Coronary Stents Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Hydrophilic Coronary Stents Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Hydrophilic Coronary Stents Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Cardionovum Basic Information And Sales Area

Table 52: Cardionovum. Products Portfolio

Table 53: Degania Silicone Basic Information And Sales Area

Table 54: Degania Silicone. Products Portfolio

Table 55: Genoss Basic Information And Sales Area

Table 56: Genoss. Products Portfolio

Table 57: Lepu Medical Basic Information And Sales Area

Table 58: Lepu Medical. Products Portfolio

Table 59: USM Healthcare Medical Devices Factory Basic Information And Sales Area

Table 60: USM Healthcare Medical Devices Factory. Products Portfolio

Table 61: Meril Life Sciences Basic Information And Sales Area

Table 62: Meril Life Sciences. Products Portfolio

Table 63: Rontis Medical Basic Information And Sales Area

Table 64: Rontis Medical. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Hydrophilic Coronary Stents Market Value (USD Million) By Region

Table 74: Global Hydrophilic Coronary Stents Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global Hydrophilic Coronary Stents Market Volume (K) By Region

Table 91: Global Hydrophilic Coronary Stents Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current Hydrophilic Coronary Stents market size?

The Hydrophilic Coronary Stents market size was estimated at USD 1.15 billion in 2023, reflecting strong adoption in North America and Europe. The figure incorporates sales of drug‑eluting and bare‑metal variants with hydrophilic coatings across both public and private hospital networks, and includes consumables for percutaneous coronary interventions.

2. What is the projected growth forecast for the market?

Analysts project the Hydrophilic Coronary Stents market to expand at a CAGR of 5.8 % from 2024 to 2032, reaching roughly USD 1.85 billion by the end of the forecast horizon. Growth is driven by aging populations and expanding PCI volumes.

3. Which key drivers are fueling market expansion?

Key drivers include the proven reduction in restenosis rates with hydrophilic coatings, rising prevalence of coronary artery disease, increasing reimbursement for minimally invasive procedures, and the shift toward single‑use catheter systems that improve procedural efficiency and patient safety.

4. What challenges could impede market growth?

Challenges stem from higher upfront costs of hydrophilic‑coated devices, stringent sterility validation requirements, competition from bioresorbable scaffolds, and physician preference for familiar bare‑metal platforms, especially in cost‑sensitive emerging markets. Regulatory delays and limited long‑term clinical data also raise adoption barriers for hospitals evaluating new product lines.

5. Which regions lead the Hydrophilic Coronary Stents market?

North America remains the dominant region, accounting for over 45 % of global revenue, driven by advanced healthcare infrastructure and high PCI procedure rates. Europe follows as the second largest, while Asia‑Pacific shows the fastest compound annual growth due to expanding cardiovascular programs.

6. Who are the top companies operating in this market?

The market is led by Medtronic, Abbott Laboratories, Boston Scientific, Terumo Corporation, and B. Braun Melsungen. These firms invest heavily in R&D, maintain extensive distribution networks, and regularly launch next‑generation hydrophilic‑coated stent platforms to capture market share.

7. What future opportunities are emerging for the market?

Future opportunities include integration of drug‑eluting technologies with hydrophilic surfaces, development of bioactive coatings that promote endothelial healing, and expansion into peripheral arterial applications. Partnerships with digital health firms to enable real‑time monitoring of stent performance also present growth avenues.

8. How is technology influencing the Hydrophilic Coronary Stents market?

Advances in nanofabrication enable ultra‑thin hydrophilic layers that reduce friction and improve deliverability. Computational modeling accelerates design cycles, while AI‑driven imaging assists physicians in selecting optimal stent sizes, collectively enhancing procedural outcomes and market adoption.

9. What is the regulatory landscape for these devices?

Hydrophilic Coronary Stents must comply with FDA Class III Premarket Approval in the United States and obtain CE Marking under the EU Medical Device Regulation. Post‑market surveillance, clinical registries, and adherence to ISO 13485 quality standards are mandatory globally.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hydrophilic Coronary Stents Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.23 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cardionovum; Degania Silicone; Genoss; Lepu Medical; USM Healthcare Medical Devices Factory; Meril Life Sciences; Rontis Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options